Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Jong-Mu Sun
CONTACT
Lead
Samsung Medical Center
Previous PD-1/PD-L1 inhibitors should be 2nd or 3rd line therapy for advanced NSCLC. There should be no systemic therapy after previous PD-1/PD-L1 therapy, before the enrollment to this study.
Age
20–90
Sex
ALL
Healthy volunteers
Not accepted